USD 507.99 million
Report ID:
SQMIG35A2569 |
Region:
Global |
Published Date: February, 2025
Pages:
219
|Tables:
89
|Figures:
76
Vagus Nerve Stimulation Market size was valued at USD 507.99 million in 2023 and is poised to grow from USD 550.15 million in 2024 to USD 1041.15 million by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).
Several pivotal factors are propelling the growth of the vagus nerve stimulation (VNS) market. These encompass the burgeoning elderly population, the introduction of technologically sophisticated products, mounting demand for VNS as a supplementary therapy, a heightened incidence of chronic ailments like migraines and epilepsy, and the conspicuous presence of unmet medical necessities within these ailment categories. Additionally, the escalating prevalence of neurological and lifestyle-linked disorders, external funding driving research and development initiatives, and the desire for less invasive surgical interventions are further galvanizing the expansion of the VNS industry.
These devices have demonstrated a 50% reduction in epileptic seizures. The substantial efficacy exhibited by VNS devices in epilepsy management, as well as their utility in treating chronic depression, are poised to be significant growth catalysts over the ensuing six years.
Nevertheless, market growth faced challenges due to reduced procedural volumes in 2020, attributed to access restrictions in hospitals amidst the pandemic. Nonetheless, the escalating teleconsultation practices for follow-ups and routine evaluations addressing epilepsy symptoms during the pandemic have substantially contributed to market improvement.
Moreover, the mounting prevalence of neurological disorders such as epilepsy, depression, and migraines, alongside the ascent of minimally invasive neurosurgical interventions, underscore the primary drivers propelling the global VNS market. According to the World Health Organization, neurological ailments contribute significantly to the global disease burden, and their impact on mortality is profound across developed and developing nations alike.
US Vagus Nerve Stimulation Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2025-2032
Global Market Size
USD 507.99 million
Largest Segment
Metallic
Fastest Growth
Metallic
Growth Rate
8.3% CAGR
To get more reports on the above market click here to Buy The Report
Global Vagus Nerve Stimulation Market is segmented by Product Type, Application, Biomaterial, End User and region. Based on Product Type, the market is segmented into Implantable VNS Devices and External VNS Devices. Based on Application, the market is segmented into Epilepsy, Depression, Migraine and Others. Based on Biomaterial, the market is segmented into Metallic, Ceramics and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The implantable VNS device segment exhibited market dominance in 2022, commanding a substantial revenue share of over 59.0%. This ascendancy can be attributed to the growing patient population grappling with various maladies like headaches, depression, and epilepsy. Implantable VNS devices hold a distinct advantage in their capacity to precisely target pain points. By delivering electrical stimulation directly to specific nerves, these devices efficiently modify nerve activity, rendering them a more potent modality for disease management.
The vagus nerve stimulation market, segmented by product into implantable and external VNS devices, showcases notable dynamics. The implantable VNS device niche is a critical resource for individuals who have not responded to conventional treatments, including anti-seizure medications and intensive depression therapies such as psychotherapy, antidepressants, and electroconvulsive therapy (ECT). On the other hand, the external VNS device sector is projected to experience the most rapid growth, with a noteworthy CAGR of 11.9% from 2023 to 2030. This rise can be attributed to an escalating number of patients afflicted with chronic disorders, an upsurge in the preference for non-invasive therapies, and the economic viability of the device.
The trajectory towards non-invasive solutions stems from the perceived adverse events linked to implantable VNS devices, both from the surgical procedure and the electrical stimulation itself. In response, non-invasive vagus nerve stimulators (nVNS) emerged to rectify the limitations of their invasive counterparts. Notable among these non-invasive options are the GammaCore Sapphire by ElectroCore and the Parasym device by Parasym Ltd., both aimed at delivering efficacious vagus nerve stimulation while circumventing the drawbacks associated with invasive approaches. This shift towards non-invasive devices aligns with the growing trend of patient preference and is expected to propel market growth in the forecast period
The metallic biomaterials segment held sway over the market landscape in 2022, commanding a revenue share surpassing 49.0%. This dominance stems from profound progress and Research and Development (R&D) strides made in the domain of vagus nerve stimulation therapies. Anticipations also indicate that this segment will persist in its prominent position until 2030. Metallic biomaterials find a prolific application in medical devices, notably implantable ones, a preference attributed to their thermal conductivity and robust mechanical attributes. Metals such as 316L stainless steel, various titanium-based alloys, gold, tantalum, silver, platinum, and cobalt-chromium alloys are favored for coating electrical implantable devices due to their anti-inflammatory properties.
In contrast, the polymeric segment is projected to record the most substantial growth rate, soaring at an impressive 11.6% from 2023 to 2030. This progress can be ascribed to the inherent flexibility advantages that polymers offer. Amid the global surge in the prevalence of stress and depression, polymers exhibit their efficacy by adapting into supportive structures encompassing electro-spun matrices, nerve conduits, and scaffolds. Their regenerative potential for damaged neural tissues underscores their prominence. Notably, polymers are an integral component in medical implantable devices, extending a wide spectrum of shapes and mechanical traits, prominently biocompatibility and bioactivity. These attributes collectively pave the way for segment expansion over the forecast period.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America asserted its dominance in the vagus nerve stimulation market, commanding a substantial share of 59.92%. This commanding presence can be attributed to several factors, notably the escalated allocation of government funds and initiatives aimed at enhancing awareness about epilepsy and challenging-to-treat depression within the region. Moreover, the region's accelerated stride in technological advancements, the notable concentration of key manufacturers, heightened investments in Research and Development (R&D), and an upsurge in governmental funding and initiatives collectively shape a landscape ripe with growth opportunities. These factors stand as cornerstones poised to propel the market towards significant expansion.
Conversely, the Asia Pacific region is poised to undergo substantial expansion, manifesting a compelling CAGR of 11.6% from 2023 to 2030. This upswing is attributed to the mounting prevalence of neurodegenerative disorders across the region, compounded by a discernible unmet need for effective and sustainable solutions. The region's heightened awareness about treatment options for neurological diseases and the refinement of clinical development frameworks within emerging economies converge to nurture an environment conducive to market expansion.
Further reinforcing the growth trajectory, developing countries such as Japan, China, and India emerge as crucibles of high-growth opportunities. The establishment of notable organizations like the Asia-Pacific Centre for Neuromodulation (APCN), mandated to spearhead research endeavors and propagate awareness regarding the manifold benefits of vagus nerve stimulation, is poised to act as a significant catalyst augmenting regional growth. As the Asia Pacific region positions itself on the precipice of transformative advancements in the healthcare sector, the vagus nerve stimulation market is set to thrive, catalyzed by a confluence of factors that stimulate awareness, innovation, and growth.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Geriatric Population
Government Funding and Initiatives
Unmet Medical Needs
High Costs
Limited Reimbursement Policies
Adverse Events and Risks
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global vagus nerve stimulation (VNS) market is characterized by a blend of established medical device manufacturers, innovative start-ups, and strategic collaborations. Leading companies such as LivaNova PLC, ElectroCore LLC, and EnteroMedics Inc. dominate the market due to their extensive product portfolios, significant investments in R&D, and established market presence. These key players focus on continuous product development, technological advancements, and expanding their geographical reach to maintain a competitive edge.
The market also witnesses the active participation of emerging players, often specializing in specific segments of VNS devices or targeting niche applications. These entrants bring innovation and fresh perspectives, driving the evolution of VNS therapies. Collaborations between established players and start-ups are becoming common, aiming to leverage complementary strengths and accelerate the development of novel solutions.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global vagus nerve stimulation market analysis, the global vagus nerve stimulation (VNS) market is poised for substantial growth, driven by a confluence of factors such as the rising prevalence of neurological disorders, technological advancements, and increasing awareness among both patients and healthcare professionals. The efficacy of VNS in treating chronic conditions like epilepsy and depression, coupled with the potential expansion of its applications to other disorders, underscores its significance in the medical landscape.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 507.99 million |
Market size value in 2032 | USD 1041.15 million |
Growth Rate | 8.3% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Million |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Vagus Nerve Stimulation Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Vagus Nerve Stimulation Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Vagus Nerve Stimulation Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Vagus Nerve Stimulation Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Vagus Nerve Stimulation Market size was valued at USD 482.85 Million in 2023 and is poised to grow from USD 535.96 Million in 2024 to USD 1235.15 Million by 2032, growing at a CAGR of 11% during the forecast period (2025-2032).
The competitive landscape of the global vagus nerve stimulation (VNS) market is characterized by a blend of established medical device manufacturers, innovative start-ups, and strategic collaborations. Leading companies such as LivaNova PLC, ElectroCore LLC, and EnteroMedics Inc. dominate the market due to their extensive product portfolios, significant investments in R&D, and established market presence. These key players focus on continuous product development, technological advancements, and expanding their geographical reach to maintain a competitive edge. 'LivaNova PLC (United Kingdom)', 'ElectroCore LLC (United States)', 'EnteroMedics Inc. (United States)', 'Boston Scientific Corporation (United States)', 'NeuroMetrix Inc. (United States)', 'Cyberonics, Inc. (a subsidiary of LivaNova PLC) (United States)', 'SetPoint Medical Corporation (United States)', 'Inspire Medical Systems, Inc. (United States)', 'NeuroPace, Inc. (United States)', 'NeuroSigma, Inc. (United States)', 'Vagus Nerve Stimulation Ltd. (Israel)', 'Endonovo Therapeutics, Inc. (United States)', 'Nevro Corp. (United States)', 'BioControl Medical (Israel)', 'Helius Medical Technologies, Inc. (United States)', 'Vivonics, Inc. (United States)', 'Bioness Inc. (United States)', 'Beijing Demax Medical Technology Co., Ltd. (China)', 'Neurowave Systems Inc. (Canada)', 'Nobel Biocare Services AG (Switzerland)'
The growing elderly population is susceptible to various neurological ailments, driving the demand for innovative treatment approaches like VNS to enhance their quality of life.
Non-Invasive VNS Solutions: The development of non-invasive VNS devices offers a more accessible and patient-friendly alternative, addressing concerns related to invasive procedures and expanding the potential patient pool.
In 2022, North America asserted its dominance in the vagus nerve stimulation market, commanding a substantial share of 59.92%. This commanding presence can be attributed to several factors, notably the escalated allocation of government funds and initiatives aimed at enhancing awareness about epilepsy and challenging-to-treat depression within the region. Moreover, the region's accelerated stride in technological advancements, the notable concentration of key manufacturers, heightened investments in Research and Development (R&D), and an upsurge in governmental funding and initiatives collectively shape a landscape ripe with growth opportunities. These factors stand as cornerstones poised to propel the market towards significant expansion.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35A2569
[email protected]
USA +1 351-333-4748